Kimura M, Tarumoto Y, Nakane S, Otomo S
Drugs Exp Clin Res. 1986;12(8):643-52.
Comparative systemic and topical toxicity in male rats treated on the dorsal skin for 14 consecutive days with a volume of 0.15 g/100 g (body weight) of 0.1% hydrocortisone 17-butyrate 21-propionate (HBP) ointment, 0.05% clobetasol propionate (CP) ointment, 0.1% predonisolone 17-valerate 21-acetate (PVA) ointment and 0.1% diflucortolone valerate (DV) ointment was studied. In all the treated groups body weight gain was suppressed, serum concentration of total cholesterol and triglycerides increased and the lymphatic tissues and skin were atrophic. The DV and CP groups had adrenal atrophy and renal lesions, and the DV group also had gastric and hepatic lesions. The systemic effect of HBP ointment was weaker than that of the other drugs (DV greater than CP much greater than PVA greater than HBP). All the drugs significantly reduced the skin fold thickness in treated areas throughout the application period. The dermal atrophic effect of HBP ointment was also relatively weaker than that of the other drugs. From the above evidence, it was concluded that HBP ointment was less toxic than the other topical corticosteroids.
研究了雄性大鼠背部皮肤连续14天涂抹0.1%丁酸氢化可的松21 - 丙酸酯（HBP）软膏、0.05%丙酸氯倍他索（CP）软膏、0.1%泼尼松龙17 - 戊酸酯21 - 乙酸酯（PVA）软膏和0.1%戊酸倍他米松（DV）软膏（剂量为0.15 g/100 g（体重））后的全身和局部毒性。在所有治疗组中，体重增加受到抑制，总胆固醇和甘油三酯的血清浓度升高，淋巴组织和皮肤萎缩。DV组和CP组出现肾上腺萎缩和肾脏病变，DV组还出现胃部和肝脏病变。HBP软膏的全身作用比其他药物弱（DV大于CP远大于PVA大于HBP）。在整个用药期间，所有药物均显著降低了治疗部位的皮肤褶皱厚度。HBP软膏的皮肤萎缩作用也相对弱于其他药物。根据上述证据，得出结论：HBP软膏的毒性低于其他局部用皮质类固醇。
